HOME >> MEDICINE >> NEWS
Other highlights in the April 21 JNCI

t density in healthy women has not been known. To investigate this, Jack Cuzick, Ph.D., of Cancer Research UK in London, and colleagues analyzed mammograms from 818 breast cancer-free women from the International Breast Cancer Intervention Study 1, a trial that tested tamoxifen's ability to prevent breast cancer in healthy women at high risk of the disease.

Treatment with tamoxifen was associated with reduced breast density, most of which occurred within the first 18 months of treatment. In women aged 45 years and younger, breast density was reduced by 13.4% on average compared with only 1.1% in women older than 55 years. The researchers hypothesize that premenopausal women experienced a larger reduction because premenopausal estrogen levels are higher and so the antiestrogenic effect of tamoxifen will be greater.

Contact: Press Office, Cancer Research UK, +44 (0) 207 061 8300, pressoffice@cancer.org.uk

Low Categories of Benign Breast Disease Still Increase Risk of Breast Cancer

There are several breast abnormalities that are not cancerous, but some of these benign conditions are associated with a greater risk of breast cancer than others. A new study has found that even women with low-category benign breast diseases are at an increased risk of breast cancer compared with women without the disease.

Jiping Wang, M.D., Ph.D., of the University of Pittsburgh, and colleagues looked at medical records for 11,307 women from the Breast Cancer Prevention Trial, 1376 of whom had the low-category benign breast disease. Women with the disease were 60% more likely than women without the disease to develop invasive breast cancer. Women with benign breast disease aged 50 years or older had a 95% increased risk of developing invasive breast cancer compared to women without benign breast disease.

Contact: Lori Garvey, National Surgical Breast and Bowel Project, (412)330-4621, <
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
20-Apr-2004


Page: 1 2 3 4

Related medicine news :

1. Other highlights in the March 16 JNCI
2. Other highlights in the March 2 JNCI
3. Other highlights in the February 2 JNCI
4. Other highlights in the January 19 JNCI
5. Other highlights in the December 15 JNCI
6. Other highlights in the December 1 JNCI
7. Other highlights in the September 15 JNCI
8. Other highlights in the April 7 JNCI
9. Other highlights in the January 7 issue of JNCI
10. Other highlights in the December 3 issue of JNCI
11. Other highlights in the November 19 issue of JNCI

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
Cached News: